Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity
Imatinib mesylate is a small-molecule tyrosine kinase inhibitor (TKi) designed to target c-ABL and BCR-ABL, approved for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors. Adverse cutaneous reactions induced by imatinib are frequent, generally moderate, and dose-dependent...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2015-05-01
|
| Series: | Turkish Journal of Hematology |
| Subjects: | |
| Online Access: | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-76402 |
| _version_ | 1797909056389644288 |
|---|---|
| author | Caterina Musolino Alessandro Allegra Carmen Mannucci Sabina Russo Andrea Alonci Valerio Maisano Gioacchino Calapai Sebastiano Gangemi |
| author_facet | Caterina Musolino Alessandro Allegra Carmen Mannucci Sabina Russo Andrea Alonci Valerio Maisano Gioacchino Calapai Sebastiano Gangemi |
| author_sort | Caterina Musolino |
| collection | DOAJ |
| description | Imatinib mesylate is a small-molecule tyrosine kinase inhibitor (TKi) designed to target c-ABL and BCR-ABL, approved for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors. Adverse cutaneous reactions induced by imatinib are frequent, generally moderate, and dose-dependent. The aim of this work was to investigate the possible contribution of interleukin (IL)-33 and IL-31, cytokines involved in disorders associated with itching, in the pathogenesis of pruritus in a patient undergoing imatinib mesylate treatment. His IL-31 and IL-33 serum levels were significantly higher than in the control group (respectively 96.6 pg/mL vs. 7.623+-7.681 pg/mL and 27.566 pg/mL vs. 6.170+-7.060 pg/mL). In light of these findings, imatinib mesylate-related symptoms of dermatologic toxicities might be related to the release of IL-31 and IL-33. In particular, it is supposable that TKi usage could cause keratinocyte injury, the release of IL-33, and the consequent interaction with its receptor on mast cells that induces the secretion of several factors capable of causing skin manifestations, including IL-31, a known pruritus-inducing cytokine. This report, to the best of our knowledge, is the first work describing the possible involvement of the IL-31/IL-33 axis in the pathogenesis of skin side effects related to imatinib mesylate treatment. |
| first_indexed | 2024-04-10T11:03:22Z |
| format | Article |
| id | doaj.art-afc49c04de1642e59edf53877ae7701b |
| institution | Directory Open Access Journal |
| issn | 1308-5263 |
| language | English |
| last_indexed | 2024-04-10T11:03:22Z |
| publishDate | 2015-05-01 |
| publisher | Galenos Publishing House |
| record_format | Article |
| series | Turkish Journal of Hematology |
| spelling | doaj.art-afc49c04de1642e59edf53877ae7701b2023-02-15T16:19:35ZengGalenos Publishing HouseTurkish Journal of Hematology1308-52632015-05-0132216817110.4274/Tjh.2014.0021TJH-76402Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin ToxicityCaterina Musolino0Alessandro Allegra1Carmen Mannucci2Sabina Russo3Andrea Alonci4Valerio Maisano5Gioacchino Calapai6Sebastiano Gangemi7University of Messina Faculty of Medicine, Department of General Surgery and Oncology, Division of Hematology, Messina, ItalyUniversity of Messina Faculty of Medicine, Department of General Surgery and Oncology, Division of Hematology, Messina, ItalyAzienda Ospedaliera Universitaria Policlinico 'G. Martino', Department of Clinical and Experimental Medicine, Operative Unit of Clinical Pharmacology, Messina, ItalyUniversity of Messina Faculty of Medicine, Department of General Surgery and Oncology, Division of Hematology, Messina, ItalyUniversity of Messina Faculty of Medicine, Department of General Surgery and Oncology, Division of Hematology, Messina, ItalyUniversity of Messina Faculty of Medicine, Department of General Surgery and Oncology, Division of Hematology, Messina, ItalyAzienda Ospedaliera Universitaria Policlinico 'G. Martino', Department of Clinical and Experimental Medicine, Operative Unit of Clinical Pharmacology, Messina, ItalyUniversity Of Messina Faculty Of Medicine, Policlinic 'g. Martino', Department Of Clinical And Experimental Medicine, Division Of Allergy And Clinical Immunology, Messina, Italy; Ifc Cnr, Messina Unit, Institute Of Clinical Physiology, Messina, ItalyImatinib mesylate is a small-molecule tyrosine kinase inhibitor (TKi) designed to target c-ABL and BCR-ABL, approved for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors. Adverse cutaneous reactions induced by imatinib are frequent, generally moderate, and dose-dependent. The aim of this work was to investigate the possible contribution of interleukin (IL)-33 and IL-31, cytokines involved in disorders associated with itching, in the pathogenesis of pruritus in a patient undergoing imatinib mesylate treatment. His IL-31 and IL-33 serum levels were significantly higher than in the control group (respectively 96.6 pg/mL vs. 7.623+-7.681 pg/mL and 27.566 pg/mL vs. 6.170+-7.060 pg/mL). In light of these findings, imatinib mesylate-related symptoms of dermatologic toxicities might be related to the release of IL-31 and IL-33. In particular, it is supposable that TKi usage could cause keratinocyte injury, the release of IL-33, and the consequent interaction with its receptor on mast cells that induces the secretion of several factors capable of causing skin manifestations, including IL-31, a known pruritus-inducing cytokine. This report, to the best of our knowledge, is the first work describing the possible involvement of the IL-31/IL-33 axis in the pathogenesis of skin side effects related to imatinib mesylate treatment.https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-76402interleukin-31 (il-31)interleukin-33 (il-33)tyrosine kinase inhibitorsimatinib mesylatechronic myeloid leukemiapruritus |
| spellingShingle | Caterina Musolino Alessandro Allegra Carmen Mannucci Sabina Russo Andrea Alonci Valerio Maisano Gioacchino Calapai Sebastiano Gangemi Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity Turkish Journal of Hematology interleukin-31 (il-31) interleukin-33 (il-33) tyrosine kinase inhibitors imatinib mesylate chronic myeloid leukemia pruritus |
| title | Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity |
| title_full | Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity |
| title_fullStr | Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity |
| title_full_unstemmed | Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity |
| title_short | Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity |
| title_sort | possible role of interleukin 31 33 axis in imatinib mesylate associated skin toxicity |
| topic | interleukin-31 (il-31) interleukin-33 (il-33) tyrosine kinase inhibitors imatinib mesylate chronic myeloid leukemia pruritus |
| url | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-76402 |
| work_keys_str_mv | AT caterinamusolino possibleroleofinterleukin3133axisinimatinibmesylateassociatedskintoxicity AT alessandroallegra possibleroleofinterleukin3133axisinimatinibmesylateassociatedskintoxicity AT carmenmannucci possibleroleofinterleukin3133axisinimatinibmesylateassociatedskintoxicity AT sabinarusso possibleroleofinterleukin3133axisinimatinibmesylateassociatedskintoxicity AT andreaalonci possibleroleofinterleukin3133axisinimatinibmesylateassociatedskintoxicity AT valeriomaisano possibleroleofinterleukin3133axisinimatinibmesylateassociatedskintoxicity AT gioacchinocalapai possibleroleofinterleukin3133axisinimatinibmesylateassociatedskintoxicity AT sebastianogangemi possibleroleofinterleukin3133axisinimatinibmesylateassociatedskintoxicity |